Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases

Abstract Antimalarial drugs (e.g. chloroquine and its close structural analogues) were developed primarily to treat malaria; however, they are beneficial for many dermatological, immunological, rheumatological and severe infectious diseases, for which they are used mostly today. Chloroquine and hydroxychloroquine, two of the most fascinating drugs developed in the last 50 years, are increasingly recognized for their effectiveness in myriad non-malarial diseases. In advanced research, chloroquine and hydroxychloroquine have been shown to have various immunomodulatory and immunosuppressive effects, and currently have established roles in the management of rheumatic diseases, lupus erythematosus (different forms) and skin diseases, and in the treatment of different forms of cancer. Recently, chloroquine analogues have also been found to have metabolic, cardiovascular, antithrombotic and antineoplastic effects. This review is concerned with the lysosomotropic, anti-inflammatory and immunomodulatory mechanisms of chloroquine, hydroxychloroquine, quinacrine and related analogues, and the current evidence for both their beneficial effects and potential adverse manifestations in various diseases.

[1]  I. Bassanetti,et al.  Oxidative stress induced by copper and iron complexes with 8-hydroxyquinoline derivatives causes paraptotic death of HeLa cancer cells. , 2014, Molecular pharmaceutics.

[2]  E. Taherian,et al.  The biological and clinical activity of anti-malarial drugs in autoimmune disorders. , 2013, Current rheumatology reviews.

[3]  H. Takayanagi,et al.  Inhibitory effect of chloroquine on bone resorption reveals the key role of lysosomes in osteoclast differentiation and function , 2012 .

[4]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[5]  A. Hoke,et al.  Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft‐versus‐host disease , 2005, American journal of hematology.

[6]  Tingting Wang,et al.  Hydroxychloroquine decreases the upregulated frequencies of Tregs in patients with oral lichen planus , 2014, Clinical Oral Investigations.

[7]  D. Gladman,et al.  The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[8]  K. Batty,et al.  Pharmacokinetics, Pharmacodynamics, and Allometric Scaling of Chloroquine in a Murine Malaria Model , 2011, Antimicrobial Agents and Chemotherapy.

[9]  Changhai Chen Development of antimalarial drugs and their application in China: a historical review , 2014, Infectious Diseases of Poverty.

[10]  I. Marsol,et al.  Antipalúdicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios , 2014 .

[11]  C. Evans,et al.  Autophagy as a modulator and target in prostate cancer , 2014, Nature Reviews Urology.

[12]  P. Saftig,et al.  Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function , 2009, Nature Reviews Molecular Cell Biology.

[13]  U. Karaçayli,et al.  Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome. , 2013, Oral health & preventive dentistry.

[14]  M. V. Van Beek,et al.  Antimalarials , 2001, Dermatologic clinics.

[15]  A. Mahajan Chapter-142 Treatment of Rheumatoid Arthritis State-of-the-Art , 2007 .

[16]  F. Ascaso,et al.  The "flying saucer" sign on spectral domain optical coherence tomography in chloroquine retinopathy. , 2013, Arthritis and rheumatism.

[17]  S. Azar,et al.  A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role , 2014, Therapeutic advances in endocrinology and metabolism.

[18]  R. Price,et al.  Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis , 2014, The Lancet. Infectious diseases.

[19]  M. Luster,et al.  Quinacrine-induced occlusive fibrosis in the human fallopian tube is due to a unique inflammatory response and modification of repair mechanisms. , 2013, Journal of reproductive immunology.

[20]  A. Bridges,et al.  Bullous rash and brown urine in a systemic lupus erythematosus patient treated with hydroxychloroquine. , 1995, Arthritis and rheumatism.

[21]  R. Vollenhoven,et al.  Treatment of rheumatoid arthritis: state of the art 2009 , 2009, Nature Reviews Rheumatology.

[22]  N. Fazel Cutaneous lichen planus: A systematic review of treatments , 2015, The Journal of dermatological treatment.

[23]  T. Tenhave,et al.  Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. , 2011, Archives of dermatology.

[24]  Y. Kato,et al.  Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI) , 2012, Modern rheumatology.

[25]  N. Mar,et al.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss , 2014, Journal of Thrombosis and Thrombolysis.

[26]  N. Thomas,et al.  Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone , 2014, Current medical research and opinion.

[27]  Shahjahan,et al.  Reemergence of chloroquine (CQ) analogs as multi-targeting antimalarial agents: a review. , 2015, European journal of medicinal chemistry.

[28]  D. Khan Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. , 2013, The journal of allergy and clinical immunology. In practice.

[29]  N. Costedoat-Chalumeau,et al.  Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? , 2015, Autoimmunity reviews.

[30]  G. Doho,et al.  Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  N. Shear,et al.  Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine: First Case Report in Canada and Review of the Literature , 2013, Journal of cutaneous medicine and surgery.

[32]  A. Gonzalez-Estrada,et al.  Sporadic porphyria cutanea tarda: treatment with chloroquine decreases hyperglycemia and reduces development of metabolic syndrome. , 2014, European journal of internal medicine.

[33]  D. Freeman,et al.  Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[34]  V. Werth,et al.  Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy , 2013, Dermatologic therapy.

[35]  A. Fabre,et al.  Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review , 2013, European heart journal. Acute cardiovascular care.

[36]  G. Oudit,et al.  Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. , 2014, The Canadian journal of cardiology.

[37]  H. Kushlaf Emerging toxic neuropathies and myopathies. , 2011, Neurologic clinics.

[38]  J. Grutters,et al.  Cytotoxic agents in sarcoidosis: which one should we choose? , 2014, Current opinion in pulmonary medicine.

[39]  K. McCrae,et al.  Recent advances in the antiphospholipid antibody syndrome , 2014, Current opinion in hematology.

[40]  K. Kirkwood,et al.  Autoimmunity to deltaNp63alpha in Chronic Ulcerative Stomatitis , 2007, Journal of dental research.

[41]  G. Chrousos,et al.  New use for old drugs? Prospective targets of chloroquines in cancer therapy. , 2014, Current drug targets.

[42]  E. Sausville,et al.  Autophagy modulation: a target for cancer treatment development , 2015, Cancer Chemotherapy and Pharmacology.

[43]  H. Sayles,et al.  Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications , 2014, Arthritis care & research.

[44]  L. Voinea,et al.  Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review , 2014, Journal of medicine and life.

[45]  P. Voulgari,et al.  Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome , 2014, The Journal of Rheumatology.

[46]  J. Bargman,et al.  The role of antimalarial agents in the treatment of SLE and lupus nephritis , 2011, Nature Reviews Nephrology.

[47]  C. Mok,et al.  Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus , 2005, Lupus.

[48]  M. Clowse,et al.  Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature , 2014, Current opinion in rheumatology.

[49]  R. López-Arellano,et al.  Distribution of Hydroxychloroquine in Lymphoid Tissue in a Rabbit Model for HIV Infection , 2013, Antimicrobial Agents and Chemotherapy.

[50]  R. Nosál',et al.  Cationic amphiphilic drugs and platelet phospholipase A(2) (cPLA(2)). , 2002, Thrombosis research.

[51]  Chih-Chuan Lin,et al.  Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia , 2006, Clinical toxicology.

[52]  Nehal A. Shah,et al.  Osseous sarcoidosis: clinical characteristics, treatment, and outcomes--experience from a large, academic hospital. , 2014, Seminars in arthritis and rheumatism.

[53]  D. Gewirtz The Autophagic Response to Radiation: Relevance for Radiation Sensitization in Cancer Therapy , 2014, Radiation research.

[54]  M. Weisman,et al.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE , 2012, Nature Reviews Rheumatology.

[55]  P. Ravaud,et al.  Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. , 2014, JAMA.

[56]  P. Maes,et al.  Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice , 2009, Antimicrobial Agents and Chemotherapy.

[57]  M. Marmor,et al.  Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. , 2015, Ophthalmology.

[58]  Razieh Soltani-Arabshahi,et al.  Chloroquine/hydroxychloroquine‐induced pemphigus , 2006, International journal of dermatology.

[59]  N. Gordon,et al.  Autophagy in osteosarcoma. , 2014, Advances in experimental medicine and biology.

[60]  P. Voulgari,et al.  Inflammatory bowel disease and lupus: a systematic review of the literature. , 2012, Journal of Crohn's & colitis.

[61]  W. A. S. Giraldo,et al.  Hiperpigmentación cutánea generalizada y melanoniquia longitudinal secundarias al tratamiento con hidroxicloroquina en lupus eritematoso sistémico , 2013 .

[62]  M. Figgie,et al.  Surgical management of the juvenile idiopathic arthritis patient with multiple joint involvement. , 2014, The Orthopedic clinics of North America.

[63]  J. Guilhou,et al.  Severe mucocutaneous necrotizing vasculitis associated with the combination of chloroquine and proguanil. , 2003, Acta dermato-venereologica.

[64]  J. Ramires,et al.  Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[65]  D. Cohen,et al.  The Natural History of Chronic Actinic Dermatitis: An Analysis at a Single Institution in the United States , 2014, Dermatitis : contact, atopic, occupational, drug.

[66]  M. Coutinho,et al.  Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. , 2002, International journal of pediatric otorhinolaryngology.

[67]  C. Onyeji,et al.  Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[68]  Isabel M. Vincent,et al.  Metabolomic-Based Strategies for Anti-Parasite Drug Discovery , 2015, Journal of biomolecular screening.

[69]  M. Santiago,et al.  Chloroquine ototoxicity , 2007, Clinical Rheumatology.

[70]  L. Requena,et al.  Wong’s dermatomyositis: a new case and review of the literature , 2013, International journal of dermatology.

[71]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[72]  H. Walia,et al.  Hydrochloroquine retinopathy: characteristic presentation with review of screening , 2013, Clinical Rheumatology.

[73]  T. Andrews,et al.  Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review , 2014, BMJ Case Reports.

[74]  L. Xing,et al.  Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. , 2014, The Journal of clinical investigation.

[75]  R. Díaz-Molina,et al.  [Effects of hydroxychloroquine on insulin sensitivity and lipid profile in patients with rheumatoid arthritis]. , 2013, Revista medica de Chile.

[76]  Bryan M Bishop,et al.  Potential and Emerging Treatment Options for Ebola Virus Disease , 2015, The Annals of pharmacotherapy.

[77]  S. Kalia,et al.  New concepts in antimalarial use and mode of action in dermatology , 2007, Dermatologic therapy.

[78]  A. Wozniacka,et al.  Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus , 2005, American journal of clinical dermatology.

[79]  D. Raoult,et al.  Tropheryma whipplei Endocarditis , 2013, Emerging infectious diseases.

[80]  I. Bassukas,et al.  Synthetic antimalarial drugs and the triggering of psoriasis – do we need disease‐specific guidelines for the management of patients with psoriasis at risk of malaria? , 2014, International journal of dermatology.

[81]  R. Asero,et al.  Treatment of Refractory Chronic Urticaria: Current and Future Therapeutic Options , 2013, American Journal of Clinical Dermatology.

[82]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[83]  L. Vilá,et al.  Multifocal osteonecrosis in systemic lupus erythematosus: case report and review of the literature , 2013, BMJ Case Reports.

[84]  L. Arnaud,et al.  Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. , 2015, Autoimmunity reviews.

[85]  M. Ward Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[86]  N. Costedoat-Chalumeau,et al.  [Neonatal lupus syndrome: Literature review]. , 2015, La Revue de medecine interne.

[87]  S. Holmes,et al.  Frontal fibrosing alopecia: a review of 60 cases. , 2012, Journal of the American Academy of Dermatology.

[88]  A. Laties,et al.  Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations. , 2014, Experimental eye research.

[89]  M. J. Leckie,et al.  Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. , 2002, Rheumatology.

[90]  A. Baibergenova,et al.  Lichen planopilaris: update on pathogenesis and treatment. , 2013, Skinmed.

[91]  J. Moss,et al.  Optimizing treatments for lymphangioleiomyomatosis , 2012, Expert review of respiratory medicine.

[92]  D. Kurahara,et al.  Pulmonary Hemosiderosis in Children with Bronchopulmonary Dysplasia , 2014, Case reports in pediatrics.

[93]  É. Oksenhendler,et al.  Granulomatous Disease in CVID: Retrospective Analysis of Clinical Characteristics and Treatment Efficacy in a Cohort of 59 Patients , 2012, Journal of Clinical Immunology.

[94]  A. Engel,et al.  Teaching NeuroImages: Hydroxychloroquine-induced vacuolar myopathy , 2013, Neurology.

[95]  E. Padilha,et al.  Evaluation of Antimalarial Activity and Toxicity of a New Primaquine Prodrug , 2014, PloS one.

[96]  E. Matteson,et al.  Rheumatoid vasculitis: an update , 2015, Current opinion in rheumatology.

[97]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[98]  K. Hahm,et al.  Chemoquiescence for Ideal Cancer Treatment and Prevention: Where Are We Now? , 2014, Journal of cancer prevention.

[99]  K. Bentsi-Enchill Pigmentary skin changes associated with ocular chloroquine toxicity in Ghana. , 1980, Tropical and geographical medicine.

[100]  V. Werth,et al.  Update on pathogenesis and treatment of CLE , 2013, Current opinion in rheumatology.

[101]  F. Müller,et al.  Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine , 2011, Antimicrobial Agents and Chemotherapy.

[102]  H. Schmid,et al.  Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. , 2003, Human pathology.

[103]  R. Vij,et al.  Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[104]  F.C. Zhang,et al.  An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine , 2014, Lupus.

[105]  A. Krettli,et al.  Antiplasmodial activity of chloroquine analogs against chloroquine-resistant parasites, docking studies and mechanisms of drug action , 2014, Malaria Journal.

[106]  A. Chopra,et al.  Effectiveness of Chloroquine and Inflammatory Cytokine Response in Patients With Early Persistent Musculoskeletal Pain and Arthritis Following Chikungunya Virus Infection , 2014, Arthritis & rheumatology.

[107]  N. Costedoat-Chalumeau,et al.  Hydroxychloroquine: a multifaceted treatment in lupus. , 2014, Presse medicale.

[108]  S. Dhaneshwar,et al.  An update on disease modifying antirheumatic drugs. , 2014, Inflammation & allergy drug targets.

[109]  S. Prusiner,et al.  Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease , 2013, Neurology.

[110]  A. Chauhan,et al.  Endocytosis of human immunodeficiency virus 1 (HIV-1) in astrocytes: a fiery path to its destination. , 2015, Microbial pathogenesis.

[111]  G. Forloni,et al.  Therapy in prion diseases. , 2013, Current topics in medicinal chemistry.

[112]  K. Gurova,et al.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. , 2009, Future oncology.

[113]  J. Wenzel,et al.  Innate Immune-Response Mechanisms in Dermatomyositis: An Update on Pathogenesis, Diagnosis and Treatment , 2014, Drugs.

[114]  J. Nunemacher,et al.  Optimal management of giant cell arteritis and polymyalgia rheumatica , 2012, Therapeutics and clinical risk management.

[115]  R. Wolf,et al.  Antimalarials: unapproved uses or indications. , 2000, Clinics in dermatology.

[116]  W. S. Sifuentes Giraldo,et al.  Generalized skin hyperpigmentation and longitudinal melanonychia secondary to treatment with hydroxychloroquine in systemic lupus erythematosus. , 2013, Reumatologia clinica.

[117]  R. Flipo,et al.  Treatment of Nongout Joint Deposition Diseases: An Update , 2014, Arthritis.

[118]  W. Peitsch,et al.  Individualizing treatment and choice of medication in lichen planus: a step by step approach , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[119]  A. Chopra,et al.  Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. , 2014, Psychosomatics.

[120]  A. Bhalla,et al.  Hydroxychloroquine’s Efficacy as an Antiplatelet Agent Study in Healthy Volunteers , 2015, Journal of cardiovascular pharmacology and therapeutics.

[121]  A. Carmichael,et al.  Fatal toxic epidermal necrolysis associated with hydroxychloroquine , 2001, Clinical and experimental dermatology.

[122]  G. Stark,et al.  Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer , 2014, Molecular Cancer Therapeutics.

[123]  N. Sharma,et al.  Unusual life-threatening adverse drug effects with chloroquine in a young girl. , 2003, Journal of postgraduate medicine.

[124]  M. González-Ortiz,et al.  Efecto de la hidroxicloroquina sobre la sensibilidad a la insulina y el perfil de lípidos en pacientes con artritis reumatoide , 2013 .

[125]  S. Wahie,et al.  Long‐term response to hydroxychloroquine in patients with discoid lupus erythematosus , 2013, The British journal of dermatology.

[126]  Duxin Sun,et al.  The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. , 2013, Biomaterials.

[127]  Jeffrey P Krise,et al.  Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. , 2007, Journal of pharmaceutical sciences.

[128]  A. Escobedo,et al.  Management of chronic Giardia infection , 2014, Expert review of anti-infective therapy.

[129]  L. Sammaritano,et al.  Rheumatoid arthritis medications and lactation , 2014, Current opinion in rheumatology.

[130]  R. Kandolf,et al.  Chloroquine cardiomyopathy – a review of the literature , 2013, Immunopharmacology and immunotoxicology.

[131]  N. Morrell,et al.  Chloroquine Prevents Progression of Experimental Pulmonary Hypertension via Inhibition of Autophagy and Lysosomal Bone Morphogenetic Protein Type II Receptor Degradation , 2013, Circulation research.

[132]  I. Olivieri,et al.  An update on the management of hepatitis C virus-related arthritis , 2014, Expert opinion on pharmacotherapy.

[133]  J. Piette,et al.  Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. , 2013, JAMA dermatology.

[134]  I. B. Marsol,et al.  Antimalarials in dermatology: mechanism of action, indications, and side effects. , 2014, Actas dermo-sifiliograficas.

[135]  C. Hewitt,et al.  Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial , 2013, Trials.